Unleash the power of extracellular vesicles (EV) to restore the natural immune function and defeat cancer.
Extracellular vesicles (EV) are a group of membranous nanoparticle-sized structures, such as exosomes and microvesicles, which are shed from almost all cells in our body and are critical in the cell-to-cell communication. EV Therapeutics develops off-the-shelf neoantigen-based immunotherapies from tumor-derived EVs (TEV) and formulates proprietary therapeutic vaccines that help modulate and boosts a patient's own immune system to enhance cancer treatment efficacy as a stand alone monotherapy or in combination with checkpoint inhibitors (e.g. anti-PD1 and anti-PD-L1).
Modified TEVs: A bridge of hope from chemo to immunotherapy
As cancer progresses, a patients' T cells, which are critical for a functioning immune system, become increasingly desensitized, exhausted and weakened, rendering checkpoint inhibitors unresponsive (i.e. cold). Our novel therapeutic approach uses nanoparticle sized extracellular vesicles (EVs) to deliver broad spectrum immune stimulating neoantigens devoid of fundamental immune suppressing factors. This revolutionary new synergistic therapeutic approach unlocks the innate T cell costimulatory function (CD28) to allow T cell activation, proliferation, migration, and penetration into the tumor microenvironment to effectively and sustainably destroy cancer cells. This effect is further amplified when combined with checkpoint inhibitors. By doing so, we create a bridge of hope for cancer patients who no longer benefit from chemotherapy and otherwise would not qualify for checkpoint inhibitor therapy.
The opportunity
Metastatic Colorectal Cancer
As the 2nd leading cause of cancer-related deaths world wide, colorectal cancer represents a high unmet medical need. In US, approximately 1.8 million new cases are diagnosed and over 50,000 deaths occur each year. Unfortunately, checkpoint inhibitors are not effective on patients with the MSS subtype, which accounts for > 85% of advanced metastatic colorectal cancers patients . Our leading candidate (EV101), has demonstrated pre-clinical efficacy across solid tumor and advanced metastatic animal models both as a monotherapy and combination therapy with checkpoint inhibitors.
Immune checkpoint Inhibitors are ineffective in > 85% of all colorectal cancers especially Micro-Satellite Stable (MSS) subtype patient population.
About Us
EV Therapeutics is a pre-clinical stage immuno-oncology biotechnology company comprised of passionate scientists, clinical and regulatory experts, and seasoned commercial leaders who are devoted to developing first-in-class therapies based on modified tumor extracellular vesicles (mTEVs) to significantly transform cancer therapy and other unmet medical needs that are addressable with our proprietary technology platform.
